ReviewJournal of molecular medicine (Berlin, Germany)1996
Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting.
Review in Journal of molecular medicine (Berlin, Germany), 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 87 citations in OpenAlex.
- POINTseq: Cell-type-specific barcoding reveals single-cell projection architecture of the mouse dopaminergic system.Neuron · 2026Article
- Cell type-specific barcoding reveals the single-neuron projectional architecture of the mouse midbrain dopaminergic system.bioRxiv : the preprint server for biology · 2026Article
- Targeted Epigenetic Activation ofBiomedicines · 2026Article
- Enhancer-based gene therapy: a new path for precision medicine.Hereditas · 2026Review
- Gene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care.Biotech (Basel (Switzerland)) · 2024Review
- Lipid-based nucleic acid therapeutics with in vivo efficacy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023Review
- Article
- CRISPR, Prime Editing, Optogenetics, and DREADDs: New Therapeutic Approaches Provided by Emerging Technologies in the Treatment of Spinal Cord Injury.Molecular neurobiology · 2020Review
- Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins.RNA (New York, N.Y.) · 2019Article
- Magnetically guided virus stamping for the targeted infection of single cells or groups of cells.Nature protocols · 2019Article
- Article
- A simple and rapid nonviral approach to efficiently transfect primary tissue-derived cells using polyethylenimine.Nature protocols · 2012Article
- Toxin-based therapeutic approaches.Toxins · 2010Review
- Gene and cell therapy for heart failure.Antioxidants & redox signaling · 2009Review
- Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.Pharmaceutical research · 2006Review
- DNA-based therapeutics and DNA delivery systems: a comprehensive review.The AAPS journal · 2005Review
- Cell targeting in anti-cancer gene therapy.The Malaysian journal of medical sciences : MJMS · 2004Article
- Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.Cancer gene therapy · 2003Article
- Receptor targeting of adeno-associated virus vectors.Gene therapy · 2003Review
- Viral vectors for gene transfer: a review of their use in the treatment of human diseases.Drugs · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene therapy is used to correct genetic defects or to deliver new therapeutic functions to the target cells. Viral vectors are employed mainly as a gene delivery system. A great variety of viral expression systems have been developed and assessed for their ability to transfer genes into somatic cells. In particular, retroviral and adenoviral mediated gene transfer have been extensively studied and improved. Preclinical and clinical studies covering a large range of genetic disorders are currently underway to solve basic issues dealing with gene transfer efficiencies, regulation of gene expression, and potential risks of the use of viral vectors. The majority of clinical gene therapy trials that employ viral vectors perform exvivo gene transfer into target cells. The main issue in potential clinical application of gene therapy is the need for increased gene transfer efficiency and target specificity associated with regulated gene expression at therapeutically relevant levels in vivo. Gene regulatory elements, such as promoters and enhancers, possess cell type specific activities and can be activated by certain induction factors (e.g., hormones, growth factors, cytokines, cytostatics, irradiation, heat shock) via responsive elements. A controlled and restricted expression of these genes can be achieved using such regulatory elements as internal promoters to drive the expression of therapeutic genes in viral vector constructs. In addition to high level and efficient gene expression, minimizing or excluding inappropriate gene expression in surrounding nontarget cells is of great importance for numerous gene therapeutic approaches. This contribution furnishes insight into the field of cell type specific promoter and enhancer systems which have been used for targeted and inducible expression of therapeutic genes in certain genetic disorders, viral infections, and malignancies. We also discuss promoters that represent attractive candidates for the construction of viral vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.